All Other Health and Personal Care Retailers (NAICS 456199) — A U.S. Industry Primer

NAICS = North American Industry Classification System, the federal scheme that sorts businesses by their primary activity.

1. Overview

NAICS 456199, "All Other Health and Personal Care Retailers," is the catch-all bin of specialty health-goods retailing — the slice of the store-based health economy that is not a pharmacy, a cosmetics counter, an eyeglass shop, or a vitamin store [1]. In practice it is built from three overlapping submarkets:

• Hearing-aid retail and fitting — hearing-aid centers that test, sell, program, and service devices.
• Home medical equipment (HME) — dealers of wheelchairs, walkers, mobility scooters, CPAP machines (continuous positive airway pressure devices for sleep apnea), oxygen concentrators, hospital beds, and incontinence, ostomy, and convalescent ("sickroom") supplies.
• Mobility, rehabilitation, and assistive equipment — often customized, clinician-fitted gear sold through referral and payer channels.

Why it matters to an investor: this is a small, unglamorous, but demographically tailwind-driven niche. Its customers skew old, disabled, or chronically ill — a base that grows automatically as the U.S. population ages. Much of the merchandise is big-ticket and, on the hearing side, largely paid out of pocket (hearing aids are famously not covered by traditional Medicare), which gives strong operators unusually high revenue per store and steady repeat demand [25].

Public and private investors reach it very differently. There is essentially no clean U.S.-listed pure play on this code. The archetypal storefronts — Miracle-Ear, Beltone, HearingLife, Connect Hearing — are U.S. retail chains owned by foreign-listed European hearing groups (Amplifon, Sonova, Demant, GN). The U.S.-listed names in the adjacent home-medical space (AdaptHealth; Accendra Health, the former Owens & Minor) are really insurance-billing home-care companies more than walk-in retailers. Most of the actual 456199 universe is thousands of small, privately owned local shops. Private investors therefore have the more direct menu: buy, build, or franchise a local operator. Sections 4 and 10 walk through both routes.

2. What it is and how it's structured

The Census definition is precise: establishments primarily engaged in retailing specialized lines of health and personal-care merchandise except drugs and medicines, cosmetics/beauty supplies/perfume, optical goods, and food/nutrition supplements [1]. Anything health-and-personal-care that lacks its own dedicated code lands here. The official illustrative examples are hearing-aid retailers, wheelchair retailers, and convalescent/sickroom-supply retailers [1].

What it explicitly excludes — the adjacent codes matter, because they carve most of the visible "health retail" economy away from this bin [1]:

• 456110 — Pharmacies and Drug Retailers (CVS, Walgreens, the drug-store aisle).
• 456120 — Cosmetics, Beauty Supplies, and Perfume Retailers (Ulta, Sephora, Sally Beauty).
• 456130 — Optical Goods Retailers (eyeglasses and contact lenses — e.g., National Vision, Warby Parker).
• 456191 — Food (Health) Supplement Retailers (vitamin and supplement shops such as GNC and Vitamin Shoppe — adjacent, not core).
• 454 — Nonstore retailers (qualifying electronic, mail-order, or direct sales).
• 621340 — Offices of Audiologists and 621399 — offices of orthotics/prosthetics practitioners: when the clinical service dominates (a licensed audiologist's practice), it is health care, not retail.
• 532283 — Home Health Equipment Rental: when the equipment is rented rather than sold, it is a rental service, not retail.
• 334510 / 339113 — manufacturing of hearing-aid or surgical/medical devices on the premises is a factory, not a store.

Those last exclusions are important for reading the numbers. A large share of durable medical equipment (DME) reaches patients through rental and insurance-billing channels (coded under health-care services or rental), not cash retail — which is why the biggest "HME" companies sit largely outside 456199 even though they sell the same goods.

Ownership mix: overwhelmingly small, independent, owner-operated stores, plus franchised hearing-aid centers (Miracle-Ear and Beltone run large franchise networks) and a thin layer of corporate-owned chains and private-equity platforms. The supplied federal statistics do not give a public-versus-private split, but the practical reality is clear: this is a private-heavy, fragmented corner of retail (see Section 3).

3. How big it is

The figures below are our ground-truth federal statistics. Receipts and concentration data are from the 2022 Economic Census; establishments, employment, and payroll are from 2023 County Business Patterns (CBP). They measure the specialty-storefront register, not total consumer spending on these goods.

SBA = Small Business Administration; its size standard is a federal contracting-program threshold, not an industry-size estimate, and it can change [5].

Revenue per store is high for retail — roughly $2.3 million per establishment and about $3.2 million per firm, with revenue per employee around $300,000+ [2][4] (mixing the 2022 receipts with 2023 store/employee counts, so treat these as approximate). The reason is that the merchandise is expensive — a fitted pair of hearing aids can run several thousand dollars; power wheelchairs and oxygen systems cost more — and selling is low-headcount and high-ticket rather than high-traffic.

It is extremely fragmented. The four largest firms hold just 15.8% of receipts; the top 8, 24.3%; the top 20, 33.1%; even the top 50 firms together only 43.5% [3]. The industry's Herfindahl-Hirschman Index (HHI) — a standard concentration gauge where anything under 1,500 is considered unconcentrated — is 96.6, i.e., effectively atomistic [3]. There is real room for regional scale, purchasing leverage, centralized billing, and acquisition-led roll-up.

The undercount caveat is significant here. The $23 billion figure understates the true consumer footprint of these goods for several reasons:

• Coverage limits. CBP counts only employer businesses; it excludes the self-employed and businesses without paid employees, and the Economic Census excludes government-operated establishments — so a long tail of one-person medical-supply and hearing shops falls below the measured total, and no industry-specific nonemployer figure is supplied [6].
• Channel leakage to other codes. Warehouse clubs (Costco is one of the largest hearing-aid sellers in America) are coded as clubs (455211); pharmacies (456110) sell blood-pressure monitors and mobility aids; e-commerce (Amazon, online CPAP-supply sites) sits under nonstore retail. Those sales are real but land outside 456199.
• Leakage to health-care services. The DME giants — Lincare, Apria, AdaptHealth, Rotech — mostly bill Medicare and insurers and are classified under health-care/rental codes, not cash retail. Their multi-billion-dollar revenues are largely invisible to this NAICS line.

So read $23 billion as "the specialty-retail register," not "the size of the hearing-aid and home-medical-goods economy," which is materially larger once rental, insurance billing, and other channels are counted.

4. The investable universe

The honest headline: for a general investor there is no clean U.S.-listed pure play on this retail code. Public companies report consolidated segments, not NAICS establishments, so treat the names below as exposure proxies, not pure plays. The relevant public equities are foreign-listed hearing groups (whose U.S. retail arms are the textbook 456199 business) plus a couple of U.S.-listed home-medical names that are more billing-services than storefront.

Public companies with exposure

Note the pattern: the actual U.S. storefronts a shopper walks into (Miracle-Ear, Beltone, HearingLife, Connect Hearing) are wholly owned subsidiaries of companies you can only buy on European exchanges. U.S. investors seeking direct equity in a hearing-retail chain buy the foreign parent (or, for GN, the over-the-counter GGNDF listing) [10].

Major private and privately controlled owners

• WS Audiology (owner of HearUSA retail clinics) — a large hearing-device maker and retailer; 2025 ownership includes the Tøpholm and Westermann families, the Lundbeck Foundation, EQT, and ATHOS KG [16].
• Starkey Hearing Technologies — privately held U.S. hearing-technology company; Bill Austin is owner and chairman [17].
• Numotion — complex-rehabilitation and mobility platform; AEA Investors took a controlling interest in 2018, and Numotion later combined with Canadian provider Motion [18].
• National Seating & Mobility — mobility/complex-rehab provider; Cinven agreed to acquire it from Court Square Capital Partners (confirm current ownership in diligence) [19].
• Rotech Healthcare — private national HME/respiratory provider; a proposed sale to Owens & Minor was terminated in 2025, so current ownership should be verified [20].
• Lincare (a Linde company) and Apria/Byram (now under Accendra Health) — national home-oxygen/HME networks, mostly services-coded.
• Costco — a top-five U.S. hearing-aid seller through in-club Hearing Aid Centers (captured within warehouse-club retailing, not 456199).
• The long tail: thousands of independent hearing centers and local medical-supply/mobility shops.

There is no dedicated NAICS-456199 ETF or index. Investors get exposure through the individual foreign listings above, diversified med-tech/hearing baskets, or private-market deals.

5. How the money works

This is not grocery-style traffic retail. Owners make money on product margin plus service attachment plus recurring aftermarket, and the economics split by submarket.

Hearing-aid retail is a high-gross-margin, professional-services-wrapped sale. A fitting bundles the device with audiology testing, custom programming, follow-up adjustments, financing, and warranties. Because most buyers pay largely out of pocket, pricing power is real but so is price sensitivity. Key levers:

• Units per store and average selling price — a few thousand dollars per pair, so a modest unit count supports a store.
• Attachment and repeat cycle — devices are replaced roughly every 4–5 years, and a satisfied base is an annuity of upgrades, batteries/domes, and second-ear sales.
• Vertical integration — the European groups own both the device factory and the retail chain, capturing manufacturing and retail margin on the same unit; this is the core logic of Amplifon buying GN's manufacturing arm (§8) [8].
• Franchise vs. corporate — Miracle-Ear and Beltone also monetize through franchise fees and device supply to independent operators, a capital-light layer on top of company-owned stores.

Home medical equipment economics hinge on reimbursement and mix. Where goods sell for cash, margins can be healthy; where they are billed to Medicare/Medicaid or private insurers, the payer sets the price and Medicare competitive bidding (§7) compresses it. HME operators live on:

• Payer mix — cash/retail vs. reimbursed, and the reimbursement rate on each SKU.
• Resupply annuities — CPAP masks, tubing, and filters need periodic replacement; this recurring stream is the profit engine, which is why the DME majors chase it aggressively.
• Density and logistics — route efficiency for delivering and setting up bulky equipment.

Mobility and rehabilitation is customized and referral-driven; the moat is clinical expertise, documentation, payer know-how, inventory, and service responsiveness rather than manufacturing scale.

Useful operating metrics across the three: same-store sales (SSS) and organic growth; revenue and gross margin per location; new-patient/referral conversion; replacement and resupply rates; payer mix and billing-denial rates; days sales outstanding (DSO, how fast billed revenue becomes cash); inventory turns and working capital; EBITDA (earnings before interest, taxes, depreciation, and amortization); and clinician productivity and patient retention. Capacity-utilization framing is not the right lens here — reimbursement quality, cash collection, and service density are.

Cyclicality: essential HME demand is relatively defensive, but reimbursement is policy-sensitive. Hearing aids and elective mobility products carry more private-pay exposure and are sensitive to consumer confidence, financing costs, and lower-priced alternatives. The common thread is big-ticket, low-frequency purchases with a recurring aftermarket — the opposite of thin-margin, fast-moving retail.

6. What drives demand

• Aging demographics — the dominant driver. People aged 65 and older were 18.0% of the U.S. population in 2024, up from 12.4% in 2004 [28]. The oldest cohort grows fastest: the 85-and-older population was about 6.1 million in 2023 and is projected to roughly double toward 13.7 million by 2040 [29]. Age-related hearing loss and mobility/respiratory decline rise steeply after 65, making this a structural, non-cyclical tailwind.
• Chronic-disease prevalence. The Centers for Disease Control and Prevention (CDC) reports that about three in four adults have at least one chronic condition and more than half have two or more — driving sleep-apnea (CPAP), diabetes, and respiratory-equipment resupply volumes [29].
• Care moving into the home. U.S. home-health spending reached $169.4 billion in 2024, up 10.2% [30] — a broader category than 456199, but it points the same direction: more medical goods delivered and serviced at home.
• Out-of-pocket affordability and coverage. Because traditional Medicare does not pay for hearing aids [25], demand is sensitive to household budgets and to whether Medicare Advantage plans include hearing benefits; any coverage expansion (see §7) would be a step-change in volume.
• The OTC hearing-aid channel. The Food and Drug Administration's (FDA) October 17, 2022 rule created a new over-the-counter (OTC) category letting adults (18+) with perceived mild-to-moderate loss buy hearing aids without a prescription or exam [21]. Early evidence suggests OTC is expanding the market (reaching younger, milder-loss buyers) more than cannibalizing prescription fittings. One market-research forecast projects the OTC segment roughly doubling from ~$437 million (2025) toward ~$884 million by 2034 [31] — a third-party projection, not a reported figure.
• Technology upgrade cycles. Bluetooth/rechargeable hearing aids and AI-based noise processing shorten replacement cycles and lift average prices; omnichannel ordering, remote support, and centralized resupply extend reach beyond individual storefronts.

Demographics provide a durable demand floor, but growth is uneven: HME rides chronic-care intensity, hearing care rides underpenetration and technology, and mobility depends heavily on service quality and payer execution.

7. Regulation

Two regimes shape the economics far more than ordinary retail rules — FDA device regulation and Medicare/CMS reimbursement.

• FDA device regulation. Hearing aids and most home medical devices are FDA-regulated. The pivotal recent change is the OTC hearing-aid final rule (effective October 2022), which distinguishes OTC devices (for adults with perceived mild-to-moderate loss) from prescription devices and opened non-clinical retail channels [21][22]. State licensing of hearing-instrument dispensers and audiologists still governs the prescription channel.
• Medicare / CMS reimbursement — the DME side. Suppliers that bill Medicare for durable medical equipment generally need accreditation from a CMS-approved organization, Medicare enrollment, and a surety bond [24]. The DMEPOS competitive bidding program (Durable Medical Equipment, Prosthetics, Orthotics, and Supplies) run by the Centers for Medicare & Medicaid Services (CMS) directly sets what suppliers are paid — a persistent margin pressure and a consolidation forcing-function [23]. Contract loss or post-payment recoupment can quickly impair cash flow.
• Medicare and hearing — an absence of coverage. Original Medicare (Parts A and B) does not cover hearing aids or fitting exams [25]. Recurring legislative efforts to change that — e.g., the Medicare Hearing Aid Coverage Act of 2025 — have not become law [26]; passage would be a major demand catalyst (a forward-looking, not settled, consideration).
• Advertising and privacy. The Federal Trade Commission (FTC) requires health-related claims to be truthful, not misleading, and backed by appropriate scientific evidence [27]. HIPAA (the Health Insurance Portability and Accountability Act) governs patient health data, and standard retail/consumer-protection and Medicaid rules also apply.

Regulation is both a barrier to entry and a recurring cost: accreditation, payer enrollment, and compliant marketing protect established operators, while audits, recalls, and misleading claims can destroy value.

8. Competitive dynamics and consolidation

The specialty-storefront layer is fragmented (HHI ~97; top-4 share ~16%) [3], and competition is usually local or network-based — organized around physician/therapist/hospital/insurer referral relationships, product availability and delivery speed, accreditation and payer contracts, clinician quality, brand trust, after-sale service, and purchasing power/centralized billing.

But the ownership behind the biggest chains is concentrating fast, driven by vertical integration between hearing-device makers and hearing retailers. The landmark event: in March 2026, Amplifon agreed to acquire GN Hearing (GN Store Nord's hearing-aid business) for about €2.3 billion (~$2.6 billion) — €1.69 billion cash plus 56 million Amplifon shares, leaving GN as Amplifon's second-largest shareholder at ~16% [8]. The deal fuses the world's largest hearing retailer with a top-tier device manufacturer, creating a vertically integrated group of ~€3.3 billion revenue and 20,000+ employees across 100+ countries, and is expected to close by the end of 2026 [8]. It continues years of roll-up in which the European majors (Amplifon, Sonova, Demant, GN, WS Audiology, Starkey) have bought up independent hearing chains and clinics [9].

Other pressure points:

• Big-box and online disruption. Costco's low-price hearing-aid centers and OTC/e-commerce channels pressure the traditional prescription-fitting model on price.
• Reimbursement-driven roll-ups on the HME side. Competitive-bidding margin squeeze has pushed HME toward scale players (AdaptHealth, Lincare, Apria/Byram, Rotech, and mobility platforms such as Numotion and National Seating & Mobility), consolidating a once-mom-and-pop field.
• Manufacturer-retailer control. As device makers own more retail, independents increasingly buy product from their own competitors — a structural squeeze fueling further consolidation.
• Deal risk is real. Owens & Minor (now Accendra Health) and Rotech terminated a proposed 2025 acquisition after concluding regulatory clearance was not viable on the expected timetable and cost [20]. The best consolidators will be those that improve service levels and cash conversion, not merely add locations — a financial roll-up that degrades repair times, patient communication, and billing accuracy turns scale into a liability.

9. Risks

• Reimbursement and policy risk (both directions). For HME, CMS competitive bidding and rate cuts compress margins [23]; for hearing, the market depends on out-of-pocket spending, so a recession dents big-ticket discretionary demand. Conversely, if Medicare added hearing coverage, incumbents' pricing models would be reshaped [25][26].
• Payer and referral concentration. Loss of payer contracts or physician/therapist referral relationships can quickly impair a local business.
• Billing and compliance exposure. Denials, recoupments, fraud allegations, and accreditation failures are live risks in Medicare-billed segments.
• Channel disruption. OTC and online sales, plus Costco's scale pricing, threaten the high-margin clinical-fitting model [21].
• Product risk. Recalls, defects, counterfeits, or supply shortages.
• Fragmentation and small-operator fragility. Thousands of sub-$10-million shops [5] have limited buying power, thin balance sheets, owner-dependence, and succession risk; labor shortages among audiologists, technicians, and assistive-technology specialists compound this.
• Roll-up execution risk. Excessive acquisition leverage, failed integrations, and working-capital stress from slow reimbursement.
• Manufacturer dependence / vertical squeeze. Independent retailers rely on a handful of device makers who increasingly own competing retail.
• Foreign-listing and FX risk for U.S. investors accessing the hearing names via European exchanges [7][10].
• Misclassification risk. Companies mixing retail, rental, manufacturing, clinical services, and nonstore sales are hard to compare on headline revenue — and "investing in 456199" as a code is not cleanly possible.

10. How to invest and the outlook

Public-market routes

There is no single U.S. ticker for this industry. Treat listed names as business-model investments, not as direct measures of the $23.04 billion NAICS market, and read segment disclosures carefully — separate organic from acquired growth, same-store sales from new locations, product margin from reimbursement margin, recurring resupply from one-time equipment sales, and cash generation from headline revenue. Practical options:

• Buy the European hearing groups whose U.S. retail chains define the category — Amplifon (Euronext Milan: AMP, Miracle-Ear), Sonova (SIX: SOON, Connect Hearing), Demant (Nasdaq Copenhagen: DEMANT, HearingLife), or GN Store Nord (Nasdaq Copenhagen: GN, also OTC: GGNDF, Beltone) [7][9][10]. These give the most direct exposure to hearing-retail economics, with FX and foreign-market caveats.
• Buy U.S.-listed home-medical exposure via AdaptHealth (Nasdaq: AHCO) or Accendra Health (NYSE: ACH, formerly Owens & Minor; Apria/Byram), understanding both are reimbursement-driven home-care/resupply companies more than walk-in retailers [11][12].
• Recognize that mass-channel exposure (Costco, pharmacy chains, Amazon, Linde/Lincare) comes only through large diversified companies where 456199 is a rounding error [15].

Private-market routes

This is fundamentally a private/SMB, franchise, and roll-up industry — the more direct way in for most investors. Realistic paths: owning or franchising a hearing-aid center (Miracle-Ear, Beltone) or an independent hearing clinic; buying or building a local medical-supply/mobility store; or private-equity roll-ups of independent hearing and HME operators — a very active theme given the fragmentation [3] and demographic tailwind. The strongest direct targets are regional HME businesses with durable payer/referral relationships, mobility dealers with strong clinical documentation and repair capability, hearing-care networks with productive locations and trusted local brands, and specialized suppliers with recurring resupply and low churn. Diligence should focus on payer contracts, denial history, accreditation, owner dependence, clinician retention, service-level data, inventory aging, working capital, referral concentration, and the quality of historical earnings.

Near-term drivers to watch (forward-looking)

• Completion and integration of the Amplifon–GN Hearing deal, and whether it triggers further vertical mergers [8].
• The trajectory of OTC hearing aids — whether they keep expanding the market or start eroding clinical-fitting margins [21][31].
• Any movement on Medicare hearing coverage and on DMEPOS reimbursement rates [23][25][26].
• The demographic base case, which remains the steady, structural support under the whole industry [28][29].

Bottom line: a small, fragmented, aging-population-levered niche with durable demand and healthy per-store economics — but one where the investable public equity mostly lives on European exchanges or in adjacent U.S. home-medical services, and where the real ownership action is franchise operation and private consolidation.

---

Sources

1. U.S. Census Bureau. 2022 NAICS Definition — 456199, All Other Health and Personal Care Retailers (definition, illustrative examples, cross-references to 456110/456120/456130/456191/454/621340/621399/532283/334510/339113). 2022. https://www.census.gov/naics/?input=456199&year=2022
2. U.S. Census Bureau. 2022 Economic Census — receipts and firm counts, NAICS 456199. 2022. https://data.census.gov/
3. U.S. Census Bureau. 2022 Economic Census — Concentration of Largest Firms (CR4/CR8/CR20/CR50 and HHI), NAICS 456199. 2025. https://data.census.gov/table/ECNSIZE2022
4. U.S. Census Bureau. County Business Patterns 2023 — establishments, employment, and payroll, NAICS 456199. 2025. https://www.census.gov/programs-surveys/cbp.html
5. U.S. Small Business Administration. Table of Size Standards (NAICS 456199, $9.5M average annual receipts). 2023. https://www.sba.gov/document/support-table-size-standards
6. U.S. Census Bureau. County Business Patterns Methodology / Understanding Economic Census Coverage (employer-only; excludes nonemployers and government). 2025–2026. https://www.census.gov/programs-surveys/cbp/technical-documentation/methodology.html
7. Amplifon S.p.A. 2024 Full-Year Results / Investor Information (~€2.5B revenue; Euronext Milan: AMP). 2024/2025. https://corporate.amplifon.com/en/investors
8. Amplifon / The Hearing Review / Bloomberg. Amplifon to Acquire GN Hearing in ~€2.3B (~$2.6B) Deal (€1.69B cash + 56M shares; ~16% GN stake; ~€3.3B combined revenue; close expected end-2026). 16 Mar 2026. https://hearingreview.com/inside-hearing/industry-news/amplifon-to-acquire-gn-hearing-in-2-6-billion-deal
9. MarketsandMarkets / industry market-share analyses. Global hearing-aid device market share — Sonova, Demant, WS Audiology, GN, Starkey. 2024. https://www.marketsandmarkets.com/ResearchInsight/hearing-aids-market.asp
10. Yahoo Finance / GN Store Nord. GN Store Nord A/S — Copenhagen listing (GN) and OTC ADR (GGNDF). 2026. https://finance.yahoo.com/quote/GGNDF/
11. AdaptHealth Corp. Fourth Quarter and Full-Year 2024 Results (~$3.26B revenue; ~660 locations across 47 states; Nasdaq: AHCO). 25 Feb 2025. https://adapthealth.com/2025/02/25/adapthealth-corp-announces-fourth-quarter-and-full-year-2024-results-and-provides-2025-outlook/
12. BusinessWire / Owens & Minor. Owens & Minor Announces Corporate Name Change to Accendra Health, Inc. (NYSE: ACH; effective year-end 2025; Apria and Byram Healthcare brands retained). 18 Dec 2025. https://www.businesswire.com/news/home/20251218694572/en/Owens-Minor-Announces-Corporate-Name-Change-to-Accendra-Health-Inc
13. Demant A/S. Our Business (HearingLife, Oticon, diagnostics; Nasdaq Copenhagen: DEMANT). 2026. https://www.demant.com/about/our-business
14. Sonova Holding AG. Sonova at a Glance (Connect Hearing, AudioNova; SIX Swiss: SOON). 2026. https://report.sonova.com/2026/en/sonova-at-a-glance
15. Linde plc / Lincare. About Lincare (home-oxygen/HME subsidiary of Linde; Nasdaq: LIN). 2026. https://www.lincare.com/en/why-lincare/about-lincare
16. WS Audiology. WSA Welcomes ATHOS KG as a New Shareholder (Tøpholm and Westermann families, Lundbeck Foundation, EQT, ATHOS KG; owns HearUSA). 2025. https://www.wsa.com/press-release/wsa-welcomes-athos-kg-as-a-new-shareholder-and-receives-new-investment-to-support-its-long-term-development/
17. Starkey Hearing Technologies. About Starkey (privately held; Bill Austin, owner and chairman). 2026. https://www.starkey.com/about-starkey-hearing
18. Numotion. AEA Investors Acquires Numotion (2018; later combined with Motion). 2018. https://www.numotion.com/news/aea-investors-lp-acquires-numotion-the-nation-s-l
19. National Seating & Mobility. Owner Enters Purchase Agreement with Cinven (from Court Square Capital Partners). 2019. https://www.nsm-seating.com/press-release/national-seating-mobility-owner-enters-purchase-agreement-with-international-private-equity-firm/
20. Owens & Minor / SEC. Owens & Minor and Rotech Healthcare Mutually Agree to Terminate Acquisition (2025); Rotech S-1 (2021). 2021/2025. https://www.owens-minor.com/press-release/owens-minor-and-rotech-healthcare-mutually-agree-to-terminate-previously-announced-acquisition/
21. U.S. Food and Drug Administration. Establishing Over-the-Counter Hearing Aids — Final Rule (effective Oct. 17, 2022); early market impact. 2022–2023. https://www.federalregister.gov/documents/2022/08/17/2022-17230/medical-devices-ear-nose-and-throat-devices-establishing-over-the-counter-hearing-aids
22. U.S. Food and Drug Administration. OTC Hearing Aids: What You Should Know. 2023. https://www.fda.gov/medical-devices/hearing-aids/otc-hearing-aids-what-you-should-know
23. Centers for Medicare & Medicaid Services. DMEPOS Competitive Bidding Program. 2025. https://www.cms.gov/newsroom/fact-sheets/durable-medical-equipment-prosthetics-orthotics-supplies-competitive-bidding-program-updates
24. Centers for Medicare & Medicaid Services. Enroll as a DMEPOS Supplier (accreditation, Medicare enrollment, surety bond). 2026. https://www.cms.gov/medicare/enrollment-renewal/providers-suppliers/durable-medical-equipment-prosthetics-orthotics-supplies-dmepos
25. Centers for Medicare & Medicaid Services / Medicare.gov. Hearing aids and exams are not covered by Original Medicare. 2025–2026. https://www.medicare.gov/coverage/hearing-aids
26. U.S. Congress. H.R.500 — Medicare Hearing Aid Coverage Act of 2025 (119th Congress; introduced, not enacted). 2025. https://www.congress.gov/bill/119th-congress/house-bill/500/text
27. Federal Trade Commission. Health Products Compliance Guidance. 2022. https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance
28. U.S. Census Bureau. Older Adults (65+ = 18.0% of U.S. population in 2024, up from 12.4% in 2004). 2025. https://www.census.gov/newsroom/press-releases/2025/older-adults-outnumber-children.html
29. Centers for Disease Control and Prevention. Chronic Conditions in Adults Age 85 and Older / About Chronic Diseases (85+ ~6.1M in 2023 → ~13.7M by 2040; ~3 in 4 adults have ≥1 chronic condition). 2025–2026. https://www.cdc.gov/nchs/data/hestat/hestat105.htm
30. Centers for Medicare & Medicaid Services. National Health Expenditures 2024 Highlights (home-health spending $169.4B, +10.2%). 2025. https://www.cms.gov/files/document/highlights.pdf
31. Global Market Insights. OTC Hearing Aids Market — ~$437.4M (2025) projected to ~$884.1M (2034). 2025. https://www.gminsights.com/industry-analysis/otc-hearing-aids-market